RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial

RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial

Abstract Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease among infants and young children worldwide, especially in low- and middle-income countries (LMICs). RSM01 is a novel, highly potent, half-life-extended anti-RSV monoclonal antibody (mAb) candi...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurelio Bonavia, Micha Levi, Harald Rouha, Adriana Badarau, Jonne Terstappen, Shayne Watson, Aparna B. Anderson, Joleen T. White, Jintanat Ananworanich, Dale Taylor, Andrijana Radivojevic, Michael Shaffer, Luisa M. Stamm, Michael W. Dunne
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Infectious Diseases
Subjects:
RSV
Lower respiratory tract infection
Monoclonal antibody
LMIC
Infants
Children
Online Access:https://doi.org/10.1186/s12879-024-10120-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12879-024-10120-w

Similar Items